C-reactive protein induces interleukin-6 and thrombospondin-1 protein and mRNA expression through activation of nuclear factor-κB in HK-2 cells

Kidney and Blood Pressure Research

Volumn 35, Issue 4, 2012, Pages 211-219

  Wang, Hai Rong ^a   Chen, De Liang ^a   Zhao, Mingming ^a   Shu, Shao Wu ^b   Xiong, Shi Xi ^a   Gan, Xue Dong ^a   Chao, Sheng Ping ^a   Cao, Jian Lei ^a  

^a WUHAN UNIVERSITY   (China)

^b State Key Laboratory of Freshwater Ecology and Biotechnology   (China)

Author keywords

C reactive protein; Interleukin 6; Mitogen activated protein kinase; Nuclear factor kappa B; Renal tubular epithelial cells; Thrombospondin 1

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTIBODY; C REACTIVE PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; PYRROLIDINE DITHIOCARBAMATE; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; INCUBATION TIME; KIDNEY CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

C-REACTIVE PROTEIN; CELL LINE; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-6; NF-KAPPA B; RNA, MESSENGER; THROMBOSPONDIN 1;

EID: 84855379331     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000332402     Document Type: Article

References (43)

1. Lin Lu, Li Jin Pu, Xue Wei Xu, et al: Association of serum levels of glycated albumin, Creactive protein and tumor necrosis factor-with the severity of coronary artery disease and renal impairment in patients with type 2 diabetes mellitus. Clin Biochem 2007; 40: 810-816.
2. Busch M, Franke S, Müller A, et al: Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. Kidney Int 2004; 66: 338-347.
3. Peppa M, Uribarri J, Cai W, Lu M, Vlassara H: Glycoxidation and inflammation in renal failure patients. Am J Kidney Dis 2004; 43: 690-695.
4. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998; 97: 425-428.
5. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
6. Biasucci LM, Liuzzo G, Buffon A, Maseri A: The variable role of inflammation in acute coronary syndromes and in restenosis. Semin Interv Cardiol 1999; 4: 105-110.
7. Gussekloo J, Schaap MCL, Frölich M, Blauw GJ, Westendorp RGJ: C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons. Arterioscler Thromb Vasc Biol 2000; 20: 1047-1051.
8. Kawahara K, Biswas KK, Unoshima M, et al: C-reactive protein induces high-mobility group box-1 protein release through activation of p38MAPK in macrophage RAW264.7 cells. Cardiovasc Pathol 2008; 17: 129-138.
9. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein increases plasminogen activator inhibitor-1 expression in human endothelial cells. Thromb Res 2008; 122: 125-133.
10. Wang H, Li J, Huang C, et al: Fluvastatin inhibits the expression of tumor necrosis factor-alpha and activation of nuclear factorkappa B in human endothelial cells stimulated by C-reactive
11. Li J, Wang H, Huang C, et al: Enhanced inflammatory response of blood monocytes to C-reactive protein in patients with unstable angina. Clin Chim Acta 2005; 352: 127-133.
12. Jinde K, Nikolic-Paterson DJ, Huang XR, et al: Tubular phenotypic change in progressive tubulointerstitial fibrosis in human glomerulonephritis. Am J Kid Dis 2001; 38: 761-769.
13. Stenina OI, Krukovets I, Wang K, et al: Increased expression of thrombospondin-1 in vessel wall of diabetic Zucker rat. Circulation 2003; 107: 3209-3215.
14. Janabi M, Yamashita S, Hirano K, et al: Oxidized LDL-induced NF-kappaB activation and monocyte-derived macrophages from CD36-deficient patients. Arterioscler Thromb Vasc Biol 2000; 20: 1953-1960.
15. Han KH, Hong K-H, Park J-H, et al: C-reactive protein promotes monocyte chemoattractant protein-1-mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Circulation 2004; 109: 2566-2571.
16. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-408.
17. Inoue K, Kawahara K, Biswas KK, Ando K, Mitsudo K, Nobuyoshi M, Maruyama I: HMGB1 expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques. Cardiovasc Pathol 2007; 16: 136-143.
18. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V: Inflammation, obesity, stress and coronary heart disease: Is interleukin-6 the link? Atherosclerosis 2000; 148: 209-214.
19. Beg AA, Finco TS, Nantermet PV, Baldwin AS Jr: Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of -B-: A mechanism for NF-B activation. Mol Cell Biol 1993; 13: 3301-3310.
20. Bang R, Marnell L, Mold C, et al: Analysis of binding sites in human C-reactive protein for Fc{gamma}RI, Fc{gamma}RIIA, and C1q by site-directed mutagenesis. J Biol Chem 2005; 280: 25095-25102.
21. Dalla Vestra M, Fioretto P: Diabetic nephropathy: Renal structural studies in type 1 and type 2 diabetic patients. Int Congr Ser 2005; 1253: 163-169.
22. Fioretto P, Bruseghin M, Barzon I, Arboita M, Dalla Vestraa M: Diabetic nephropathy: An update on renal structure. Int Congr Ser 2007; 1303: 51-59.
23. Bonnefoy A, Moura R, Hoylaerts MF: The evolving role of thrombospondin-1 in hemostasis and vascular biology. Cell Mol Life Sci 2008,65: 713-727.
24. Vickers MA, Green FR, Terry C, et al: Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein. Cardiovasc Res 2002; 53: 1029-1034.
25. Yeh ET, Anderson HV, Pasceri V, Willerson JT: C-reactive protein: linking inflammation to cardiovascular complications. Circulation 2001; 104: 974-975.
26. Tomai F, Crea F, Gaspardone A, et al: Unstable angina and elevated C-reactive protein levels predict enhanced vasoreactivity of the culprit lesion. Circulation 2002; 104: 1471-1476.
27. Nishikawa M, Myoui A, Tomita T, et al: Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. Arthritis Rheum 2003;48: 2670-2681.
28. Kuldo JM, Westra J, Asgeirsdottir SA, et al: Differential effects of NF-{kappa}B and p38 MAPK inhibitors and combinations thereof on TNF-{alpha}- and IL-1{beta}-induced proinflammatory status of endothelial cells in vitro. Am J Physiol Cell Physiol 2005; 289: 1229-1239.
29. Pepys MB, Hirschfield GM, Tennent GA, et al: Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006; 440: 1217-1221.
30. Johansen C, Funding AT, Otkjaer K, et al: Protein expression of TNF-{alpha} in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2. J Immunol 2006; 176: 1431-1438.
31. Perlstein RS, Whitnall MH, Abrams JS, Mougey EH, Neta R: Synergistic roles of interleukin-6, interleukin-1, and tumor necrosis factor in the adrenocorticotropin response to bacterial lipopolysaccharide in vivo: Synergistic roles of interleukin-6, interleukin-1, and tumor necrosis factor in the adrenocorticotropin response to bacterial lipopolysaccharide in vivo. Endocrinology 1993; 132: 946-952.
32. Münzel D, Lehle K, Haubner F, et al: Impact of diabetic serum on endothelial cells: An invitro-analysis of endothelial dysfunction in diabetes mellitus type 2. Biochem Biophys Res Commun 2007; 362: 238-244.
33. Brennan P, O'Neill LA: 2-mercaptoethanol restores the ability of nuclear factor kappa B (NF kappa B) to bind DNA in nuclear extracts from interleukin 1-treated cells incubated with pyrollidine dithiocarbamate (PDTC): Evidence for oxidation of glutathione in the mechanism of inhibition of NF kappa B by PDTC. Biochem J 1996; 320: 975-981.
34. Kalinina N, Agrotis A, Antropova Y, DiVitto G, Kanellakis P, Kostolias G, et al: Increased expression of the DNA-binding cytokine IL-6 in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2004; 24: 241-247.
35. Verma S, Li SH, Badiwala MV, et al: Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002; 23: 1890-1896.
36. Thieringer R, Fenyk-Melody JE, Le Grand CB, et al: Activation of peroxisome proliferator-activated receptor gamma does not inhibit IL-6 or TNF-alpha responses of macrophages to lipopolysaccharide in vitro or in vivo. Immunology 2000; 164: 1046-1054.
37. Tang D, Shi Y, Kang R, et al: Hydrogen peroxide stimulates macrophages and monocytes to actively release HMGB. J Leukoc Biol 2007; 81: 741-747.
38. Argania H, Aghaeishahsavarib M, Noroozianavval M, et al: Effects of losartan and enalapril on high-sensitivity C-reactive protein and total antioxidant in renal transplant recipients with renin-angiotensin system polymorphisms. Transplant Proc 2008; 40: 16-21.
39. Maeda S: Do inflammatory cytokine genes confer susceptibility to diabetic nephropathy? Kidney Int 2008; 74: 413-415.
40. Mineo C, Gormley AK, Yuhanna IS, et al: FcgammaRIIB mediates C-reactive protein inhibition of endothelial NO synthase. Circ Res 2005; 97: 1124-1131.
41. Baer PC, Gauer S, Wegner B, Schubert R, Geiger H: C-reactive protein induced activation of MAP-K and RANTES in human renal distal tubular epithelial cells in vitro. Clin Nephrol 2006; 66: 177-183.
42. Chang JW, Kim CS, Kim SB, et al: C-reactive protein induces NF-kappaB activation through intracellular calcium and ROS in human mesangial cells. Nephron Exp Nephrol 2005; 101:e165-e172.
43. Patel DN, King CA, Bailey SR, et al: Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2-dependent NF- B and C/EBP - . J Biol Chem 2007; 282: 27229-27238.